[Experimental studies of VEGF-C gene for the treatment of chronic obstructive lymphedema in mouse tail model].
OBJECTIVE
To study the therapeutic effect of vascular endothelial growth factor C (VEGF-C) gene for chronic obstructive lymphedema in mouse tail model which may provide a new treatment for lymphedema.


METHODS
RT-PCR and immunoabsorption were applied to detect VEGF-C gene expression in fibroblasts and secretion of VEGF-C protein in COS7 cells respectively after pCDNA3.1 (+) VEGF-C transfection. A mouse tail model of chronic obstructive lymphedema was created. Then the pcDNA3.1-VEGF-C plasmid was injected into the tail. The effect of modulating lymphangiogenesis was observed.


RESULTS
Compared with control group, overexpression of VEGF-C enhanced lymphangiogenesis in vivo and mouse tail skin suffering chronic obstructive lymphedema was improved by VEGF-C gene significantly.


CONCLUSIONS
VEGF-C can improve the lymphedema through enhancing lymphangiogenesis.
Hu
Xue-Qing
XQ
Department of Plastic Surgery, 2nd Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
Jiang
Zhao-Hua
ZH
Liu
Ning-Fei
NF
D000818:Animals; D019556:COS Cells; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D004195:Disease Models, Animal; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D008209:Lymphedema / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids; D014162:Transfection; D042582:Vascular Endothelial Growth Factor C / Q000235:genetics*
D042582:Vascular Endothelial Growth Factor C